Associated tags: ART, Patient, Coma, Human, Intubation, OXY, LOI, The Act, 3rd Floor, United, Act, Form, Sale, Regulation D, Workflow, Ministry, Shamir Medical Center, Food and Drug Administration, Food, Intensive care unit, FDA, Device, Security (finance)
Retrieved on:
Thursday, February 8, 2024
RA'ANANA, Israel, Feb. 8, 2024 /PRNewswire/ -- Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, has announced the signing of a non-binding Letter of Intent (LOI) with Shamir Medical Center (Assaf Harofeh), a renowned healthcare institution in central Israel. The Company plans to extend collaborations with further leading Israeli medical centers as part of a wider clinical deployment strategy.
Key Points:
- The Company plans to extend collaborations with further leading Israeli medical centers as part of a wider clinical deployment strategy.
- The LOI solidifies the mutual commitment of both parties to assess the integration and performance of the INSPIRA™ ART100 device ("Device) within Shamir Medical Center's clinical environment.
- This includes evaluating the device's fit with the hospital's clinical needs, efficiency in workflow, and overall impact on healthcare delivery.
- The evaluation will be led by Dr. Eduard Ilgiyaev, Director of the Intensive Care Unit at Shamir Medical Center and a leading pioneer of critical care medicine in Israel.
Retrieved on:
Thursday, December 28, 2023
The aggregate gross proceeds from the offering were approximately $3.88 million, before deducting placement agent fees and other estimated offering expenses.
Key Points:
- The aggregate gross proceeds from the offering were approximately $3.88 million, before deducting placement agent fees and other estimated offering expenses.
- The securities described above (excluding the unregistered warrants and the ordinary shares underlying the unregistered warrants) were offered and sold by the Company in a registered direct offering pursuant to a "shelf" registration statement on Form F-3 (Registration No.
- The offering of such securities in the registered direct offering were made only by means of a prospectus supplement that forms a part of the registration statement.
- A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering was filed with the SEC and is available on the SEC's website located at http://www.sec.gov.
Retrieved on:
Thursday, December 22, 2022
Human,
Wall Street,
Patient,
Failure rate,
Blue Chips,
Intubation,
Interview,
Proton Inspira,
ART,
RIAS,
Bloomberg Television,
OXY,
Annual report,
City,
Unitary state,
Coma,
Television,
Risk,
Research,
Security (finance),
Bloomberg ORLANDO, Fla, Dec. 22, 2022 /PRNewswire/ -- RedChip Companies will air an interview with Inspira™ Technologies OXY B.H.N.
Key Points:
- ORLANDO, Fla, Dec. 22, 2022 /PRNewswire/ -- RedChip Companies will air an interview with Inspira™ Technologies OXY B.H.N.
- Ltd. (Nasdaq: IINN) ( Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, on The RedChip Money Report® on Bloomberg TV, this Saturday, December 24, at 7 p.m. Eastern Time (ET).
- The RedChip Money Report® is produced by RedChip Companies Inc., an international investor relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today™.
- "The RedChip Money Report®" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
